Literature DB >> 11114167

Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication.

P Secchiero1, D Zella, S Curreli, P Mirandola, S Capitani, R C Gallo, G Zauli.   

Abstract

We show here that HIV type 1 (HIV-1) Tat protein, in combination with anti-CD3/CD28 mAbs, promotes IL-2 production and proliferation of primary CD4(+) T lymphocytes, obtained from HIV-1-seronegative donors. This effect was observed when Tat was immobilized on a solid support, but it was not observed with soluble Tat. Such hyperactivation was accomplished by recruiting the rolipram-sensitive cyclic nucleoside phosphodiesterase 4 and resulted in increased susceptibility to HIV-1 infection. Accordingly, rolipram potently inhibited HIV-1 replication in cultures stimulated by anti-CD3/CD28 +/- Tat. These results add to the concept that decreasing Tat activity is an important addition to anti-HIV-1 therapy, and they suggest a target for anti-HIV-1 chemotherapy, phosphodiesterase 4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114167      PMCID: PMC18968          DOI: 10.1073/pnas.011512398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Phorbol myristate acetate stimulation of lymphocyte guanylate cyclase and cyclic guanosine 3':5'-monophosphate phosphodiesterase and reduction of adenylate cyclase.

Authors:  R G Coffey; J W Hadden
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

Review 2.  Control of RNA initiation and elongation at the HIV-1 promoter.

Authors:  K A Jones; B M Peterlin
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

3.  Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4.

Authors:  Y Sun; L Li; F Lau; J A Beavo; E A Clark
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

4.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

5.  Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation.

Authors:  C Guntermann; B J Murphy; R Zheng; A Qureshi; P A Eagles; K E Nye
Journal:  Biochem Biophys Res Commun       Date:  1999-03-16       Impact factor: 3.575

6.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.

Authors:  B Ensoli; G Barillari; S Z Salahuddin; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

7.  The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.

Authors:  G Barillari; R Gendelman; R C Gallo; B Ensoli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.

Authors:  C J Li; D J Friedman; C Wang; V Metelev; A B Pardee
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

9.  Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels.

Authors:  E D Anastassiou; F Paliogianni; J P Balow; H Yamada; D T Boumpas
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

10.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Authors:  C D Pauza; P Trivedi; M Wallace; T J Ruckwardt; H Le Buanec; W Lu; B Bizzini; A Burny; D Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  8 in total

1.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses.

Authors:  Agnès Vendeville; Fabienne Rayne; Anne Bonhoure; Nadir Bettache; Philippe Montcourrier; Bruno Beaumelle
Journal:  Mol Biol Cell       Date:  2004-03-12       Impact factor: 4.138

3.  The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei.

Authors:  Roya Zoraghi; Thomas Seebeck
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

Review 4.  Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions.

Authors:  Luisa Minghetti; Sergio Visentin; Mario Patrizio; Laura Franchini; Maria Antonietta Ajmone-Cat; Giulio Levi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

5.  Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.

Authors:  Tracy J Ruckwardt; Ilia Tikhonov; Shannon Berg; Glen S Hatfield; Angelika Chandra; Prakash Chandra; Bruce Gilliam; Robert R Redfield; Robert C Gallo; C David Pauza
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 6.  PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.

Authors:  Claire Lugnier; Hayder M Al-Kuraishy; Eric Rousseau
Journal:  Biochem Pharmacol       Date:  2021-01-28       Impact factor: 6.100

7.  The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.

Authors:  Francesco Nicoli; Valentina Finessi; Mariaconcetta Sicurella; Lara Rizzotto; Eleonora Gallerani; Federica Destro; Aurelio Cafaro; Peggy Marconi; Antonella Caputo; Barbara Ensoli; Riccardo Gavioli
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

Review 8.  Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Authors:  Shu-Juan Zhou; Jia Wei; Shu Su; Fang-Jun Chen; Yu-Dong Qiu; Bao-Rui Liu
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.